Premium: Vaccine makers looking to spend, spend, spend after massive Covid windfall

Vaccine maker Pfizer's share price has more than doubled since the pandemic began, and the company's revenue is set to pass a new barrier of $100bn this year.
Published on
Loading content, please wait...
BizNews
www.biznews.com